Covid-19 roundup: Ada­gio plans to sub­mit EUA by Q2 in 2022; HIPRA to en­ter PhII tri­als

Ada­gio plans to sub­mit an EUA for its mon­o­clon­al an­ti­body against Covid-19 in Q2 2022, the com­pa­ny an­nounced in its Q3 up­date.

The sub­mis­sion will be based on the com­pa­ny’s STAMP tri­al of new­ly di­ag­nosed Covid-19 pa­tients. The in­ves­ti­ga­tion­al mAb is de­signed to of­fer broad neu­tral­iz­ing ac­tiv­i­ty against  SARS-CoV-2, in­clud­ing many of the dom­i­nat­ing vari­ants.

Ada­gio has al­so tout­ed ADG20 as an al­ter­na­tive treat­ment for those who will be bad can­di­dates for the pills Mer­ck and Pfiz­er have brought for­ward. But new pills brought for­ward from these com­pa­nies have the po­ten­tial to cut in­to its mar­ket. And they’ve not­ed their in­jectable for­mu­la­tions than mon­o­clon­al an­ti­bod­ies that have to be giv­en by IV, al­though ri­vals such as Vir and Re­gen­eron are work­ing on sim­i­lar for­mu­la­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER